Literature DB >> 31940047

A New Generation of Treatments for Itch.

Emilie Fowler, Gil Yosipovitch.   

Abstract

For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

Entities:  

Keywords:  antipruritics; cytokines; pruritus; unmyelinated nerve fibers

Mesh:

Substances:

Year:  2020        PMID: 31940047      PMCID: PMC9128916          DOI: 10.2340/00015555-3347

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  54 in total

1.  Anti-pruritic efficacies of doxycycline and erythromycin in the treatment of acne vulgaris: A randomized single-blinded pilot study.

Authors:  Taige Cao; Eugene Sern-Ting Tan; Yiong Huak Chan; Gil Yosipovitch; Hong Liang Tey
Journal:  Indian J Dermatol Venereol Leprol       Date:  2018 Jul-Aug       Impact factor: 2.545

2.  Efficacy of a topical proteinase-activated receptor-2 inhibitor on cowhage-induced pruritus: a randomized placebo-controlled double-blind study.

Authors:  T Cao; W D Tan; H Kim; H L Tey
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-09-12       Impact factor: 6.166

3.  Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.

Authors:  Takashi Hashimoto; Kent Sakai; Kristen M Sanders; Gil Yosipovitch; Tasuku Akiyama
Journal:  Acta Derm Venereol       Date:  2019-03-01       Impact factor: 4.437

Review 4.  Mechanisms and consequences of Jak-STAT signaling in the immune system.

Authors:  Alejandro V Villarino; Yuka Kanno; John J O'Shea
Journal:  Nat Immunol       Date:  2017-03-22       Impact factor: 25.606

5.  Itching as a systemic disease.

Authors:  Takashi Hashimoto; Gil Yosipovitch
Journal:  J Allergy Clin Immunol       Date:  2019-04-17       Impact factor: 10.793

6.  Psychosomatic factors in pruritus.

Authors:  Hong Liang Tey; Joanna Wallengren; Gil Yosipovitch
Journal:  Clin Dermatol       Date:  2013 Jan-Feb       Impact factor: 3.541

7.  Butorphanol for treatment of intractable pruritus.

Authors:  Aerlyn G Dawn; Gil Yosipovitch
Journal:  J Am Acad Dermatol       Date:  2006-01-18       Impact factor: 11.527

8.  Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.

Authors:  Emma Guttman-Yassky; Jonathan I Silverberg; Osamu Nemoto; Seth B Forman; August Wilke; Randy Prescilla; Amparo de la Peña; Fabio P Nunes; Jonathan Janes; Margaret Gamalo; David Donley; Jim Paik; Amy M DeLozier; Brian J Nickoloff; Eric L Simpson
Journal:  J Am Acad Dermatol       Date:  2018-02-02       Impact factor: 11.527

Review 9.  Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.

Authors:  M Furue; K Yamamura; M Kido-Nakahara; T Nakahara; Y Fukui
Journal:  Allergy       Date:  2017-07-20       Impact factor: 13.146

10.  A successful case of dupilumab treatment for severe uremic pruritus.

Authors:  Jonathan I Silverberg; Joaquin Brieva
Journal:  JAAD Case Rep       Date:  2019-04-03
View more
  8 in total

1.  Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch.

Authors:  Johannes Wohlrab; David Stintzing; Luise Schultz; Konstantin Jügelt; Olaf H-U Schroeder
Journal:  Skin Pharmacol Physiol       Date:  2021-09-16       Impact factor: 3.479

Review 2.  Prurigo Simplex or "Itchy Red Bump" Disease: Review and Case Series.

Authors:  Joanna Wallengren
Journal:  Acta Derm Venereol       Date:  2021-09-03       Impact factor: 3.875

3.  Ode to Salt: Commentary on "Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity".

Authors:  Theodora M Mauro
Journal:  J Invest Dermatol       Date:  2021-09-24       Impact factor: 7.590

Review 4.  Molecular and Cellular Mechanisms of Itch in Psoriasis.

Authors:  Eriko Komiya; Mitsutoshi Tominaga; Yayoi Kamata; Yasushi Suga; Kenji Takamori
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

5.  Why Do Patients in the United States Seek Care from Dermatologists?

Authors:  Gabrielle M Peck; Forrest A Roberson; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-14

6.  Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

Authors:  Sarina Elmariah; Sarah Chisolm; Thomas Sciascia; Shawn G Kwatra
Journal:  JAAD Int       Date:  2022-04-20

Review 7.  Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.

Authors:  Lai-San Wong; Yu-Ta Yen
Journal:  Diagnostics (Basel)       Date:  2022-07-21

Review 8.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.